In this work, the synthesis of the cannabinoid receptor 1 neutral antagonists 8-chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-4,5-dihydrobenzo-1H-6-oxa-cyclohepta[1,2-c] pyrazole-3-carboxamide 1a and its deaza N-cyclohexyl analogue 1b has led to a deepening of the structure-activity studies of this class of compounds. A series of novel 4,5-dihydrobenzo-oxa-cycloheptapyrazoles analogues of 1a,b, derivatives 1c-j, was synthesized, and their affinity towards cannabinoid receptors was determined. Representative terms were evaluated using in vitro tests and isolated organ assays. Among the derivatives, 1d and 1e resulted in the most potent CB1 receptor ligands (KiCB1 = 35 nM and 21.70 nM, respectively). Interestingly, both in vitro tests and isolated organ assays evidenced CB1 antagonist activity for the majority of the new compounds, excluding compound 1e, which showed a CB1 partial agonist behaviour. CB1 antagonist activity of 1b was further confirmed by a mouse gastrointestinal transit assay. Significant activity of the new CB1 antagonists towards food intake was showed by preliminary acute assays, evidencing the potentiality of these new derivatives in the treatment of obesity.

Murineddu, G., Asproni, B., Corona, P., Piras, S., Lazzari, P., Ruiu, S., et al. (2019). Development of oxygen-bridged pyrazole-based structures as cannabinoid receptor 1 ligands. MOLECULES, 24(9) [10.3390/molecules24091656].

Development of oxygen-bridged pyrazole-based structures as cannabinoid receptor 1 ligands

Legnani L.;
2019

Abstract

In this work, the synthesis of the cannabinoid receptor 1 neutral antagonists 8-chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-4,5-dihydrobenzo-1H-6-oxa-cyclohepta[1,2-c] pyrazole-3-carboxamide 1a and its deaza N-cyclohexyl analogue 1b has led to a deepening of the structure-activity studies of this class of compounds. A series of novel 4,5-dihydrobenzo-oxa-cycloheptapyrazoles analogues of 1a,b, derivatives 1c-j, was synthesized, and their affinity towards cannabinoid receptors was determined. Representative terms were evaluated using in vitro tests and isolated organ assays. Among the derivatives, 1d and 1e resulted in the most potent CB1 receptor ligands (KiCB1 = 35 nM and 21.70 nM, respectively). Interestingly, both in vitro tests and isolated organ assays evidenced CB1 antagonist activity for the majority of the new compounds, excluding compound 1e, which showed a CB1 partial agonist behaviour. CB1 antagonist activity of 1b was further confirmed by a mouse gastrointestinal transit assay. Significant activity of the new CB1 antagonists towards food intake was showed by preliminary acute assays, evidencing the potentiality of these new derivatives in the treatment of obesity.
Articolo in rivista - Articolo scientifico
Cannabinoid receptor 1 neutral antagonists; Food intake; Gastrointestinal transit; Modelling studies; Structure-activity relationship studies; Synthesis;
English
Murineddu, G., Asproni, B., Corona, P., Piras, S., Lazzari, P., Ruiu, S., et al. (2019). Development of oxygen-bridged pyrazole-based structures as cannabinoid receptor 1 ligands. MOLECULES, 24(9) [10.3390/molecules24091656].
Murineddu, G; Asproni, B; Corona, P; Piras, S; Lazzari, P; Ruiu, S; Legnani, L; Toma, L; Pinna, G
File in questo prodotto:
File Dimensione Formato  
Development of oxygen-bridged pyrazole.pdf

Solo gestori archivio

Dimensione 5.9 MB
Formato Adobe PDF
5.9 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/352015
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
Social impact